Get the Stockscreener App
742.12
0.46%
3.40
After Hours:
742.12
Regeneron Pharmaceuticals Inc stock is traded at $742.12, with a volume of 626.38K.
It is up +0.46% in the last 24 hours and down -10.34% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
See More
Previous Close:
$738.72
Open:
$738.05
24h Volume:
626.38K
Relative Volume:
0.85
Market Cap:
$76.40B
Revenue:
$14.92B
Net Income/Loss:
$4.42B
P/E Ratio:
18.08
EPS:
41.0422
Net Cash Flow:
$3.79B
1W Performance:
-2.13%
1M Performance:
-10.34%
6M Performance:
-2.39%
1Y Performance:
+27.24%
1-Day Range:
$734.18
$753.68
1-Week Range:
$722.02
$777.43
52-Week Range:
$541.00
$859.34
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
742.12 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
505.64 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
196.48 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
928.44 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
200.87 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-26 | Resumed | Piper Sandler | Overweight |
| Mar-06-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-03-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Sanofi Puts Up $1B to Expand Regeneron Alliance and Develop Next-Gen Dupixent - MedCity News
Baird reiterates Regeneron stock rating on Sanofi collaboration By Investing.com - Investing.com Canada
Sanofi To Pay Regeneron Up To $8B In Immunology Alliance - Law360
REGN Maintained by Jefferies -- Price Target Raised to $930 - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $930.00 - MarketBeat
Sanofi Commits Up to $8 Billion to Expand Regeneron Alliance on Next-Gen Antibodies - finance.biggo.com
Regeneron stock after-hours at EUR 660.45: minus 1.31 percent versus prior close - AD HOC NEWS
Jefferies raises Regeneron stock price target to $930 on partnership By Investing.com - Investing.com Canada
Regeneron Pharmaceuticals (REGN) Reports Promising Ubamatamab Tr - GuruFocus
Regeneron And Sanofi Announce A Win-Win Collaboration Expansion (NASDAQ:REGN) - Seeking Alpha
Regeneron Pharmaceuticals (REGN) Reports Promising Phase 1/2 Tri - GuruFocus
Why Regeneron (REGN) Stock Is Trading Lower Today - FinancialContent
Regeneron posts trial data for ovarian cancer therapy (REGN:NASDAQ) - Seeking Alpha
Regeneron Pharmaceuticals (REGN) Unveils Positive Phase 2 COURAG - GuruFocus
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
Sanofi and Regeneron expand global alliance - The Pharma Letter
Regeneron Pharmaceuticals Says Ubamatamab Show 73% Objective Response Rate & 11-Month Median PFS In LGSOC Patients - TradingView
Sanofi to ‘ignite’ R&D in $8B deal with longstanding partner Regeneron - BioWorld News
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC) - The Manila Times
Regeneron reports 73% response rate for ovarian cancer drug trial By Investing.com - Investing.com Canada
Sanofi, Regeneron broaden alliance to find their next Dupixent - Yahoo Finance
Patients in a small study had a median 11 months without ovarian cancer worsening on an experimental drug. - Stock Titan
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss - marketscreener.com
Sanofi, Regeneron to Expand Alliance in Up to $8 Billion Deal - WSJ
BMO reiterates Regeneron stock Outperform on Sanofi deal expansion By Investing.com - Investing.com Canada
Sanofi Deepens 20-Year Drug Development Pact With Regeneron, Pledges Up to $8 Billion - Benzinga
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion - MarketBeat
REGN: Expanded alliance targets next-gen type 2 medicines with equal cost/profit sharing and $8B in payments - TradingView
REGN Upgraded by Argus Research -- Price Target Announced at $85 - GuruFocus
Argus upgrades Regeneron stock to Buy with USD 850 target - AD HOC NEWS
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor - biospace.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Argus - MarketBeat
Upcoming Webinar Hosted by Xtalks: Inside Regeneron's Path to Scientific Intelligence and R&D Efficiency - PR Newswire
Regeneron Pharmaceuticals, Inc. (REGN) Stock Forecasts - Yahoo Finance
Argus upgrades Regeneron stock rating to buy on Dupixent growth By Investing.com - Investing.com Canada
BreakingviewsCOMMENTARY: Sanofi’s Regeneron fix requires extra shot of M&A - reuters.com
Regeneron Pharmaceuticals, Inc. (REGN) Stock Price, News, Quote & History - Yahoo Finance
Sanofi and Regeneron expand immunology partnership to the tune of $8bn - Pharmaceutical Technology
Sanofi to invest up to $8bn to expand alliance with Regeneron - marketscreener.com
REGN Stock In Focus: Sanofi Expands Immunology Deal With $1B Upfront Payment And 4 New Antibodies - Stocktwits
Sanofi expands Regeneron partnership with up to $8 billion deal i - Global Banking & Finance Review
Sanofi Expands Collaboration with Regeneron in Immunology with $10 Billion Upfront Payment - GuruFocus
Regeneron, Sanofi expand alliance with $1 billion upfront deal By Investing.com - Investing.com Canada
Regeneron drug said to cut muscle loss when combined with Novo's semaglutide (REGN:NASDAQ) - Seeking Alpha
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion - Yahoo Finance
Sanofi and Regeneron Expand Antibody Collaboration - marketscreener.com
Sanofi, Regeneron expand tie-up with $8 billion drug-development deal, settle legal dispute - marketscreener.com
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies - The Manila Times
Regeneron and Sanofi Expand Long-Standing Collaboration to Add Next-Generation Long-Acting Immunology Antibodies in Deal Worth Up to $8 Billion - Quiver Quantitative
REGN: Expanded partnership targets next-gen immunology therapies, sharing costs, profits, and innovation - TradingView
Regeneron (REGN) Grants One-Time Performance Awards to CEO and CSO, Forms New Subsidiary - GuruFocus
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Regeneron Pharmaceuticals Inc Stock (REGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McCourt Marion | EVP Commercial |
Sep 03 '26 |
Sale |
857.39 |
1,131 |
969,708 |
12,003 |
| Guarini Kathryn | Director |
Sep 02 '26 |
Option Exercise |
719.37 |
400 |
287,748 |
1,003 |
| Guarini Kathryn | Director |
Sep 02 '26 |
Sale |
850.00 |
400 |
340,000 |
603 |
4.81%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):